These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10534147)

  • 81. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Jacobson JM; Routy JP; Welles S; DeBenedette M; Tcherepanova I; Angel JB; Asmuth DM; Stein DK; Baril JG; McKellar M; Margolis DM; Trottier B; Wood K; Nicolette C
    J Acquir Immune Defic Syndr; 2016 May; 72(1):31-8. PubMed ID: 26751016
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
    MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
    HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM;
    AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients.
    Weinfurt KP; Willke RJ; Glick HA; Freimuth WW; Schulman KA
    Med Care; 2000 Apr; 38(4):404-10. PubMed ID: 10752972
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Placebo-controlled trial of cyclosporin-A in HIV-1 disease: implications for solid organ transplantation.
    Calabrese LH; Lederman MM; Spritzler J; Coombs RW; Fox L; Schock B; Yen-Lieberman B; Johnson R; Mildvan D; Parekh N;
    J Acquir Immune Defic Syndr; 2002 Apr; 29(4):356-62. PubMed ID: 11917239
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A double-blind, randomized controlled trial to examine the effect of Moringa oleifera leaf powder supplementation on the immune status and anthropometric parameters of adult HIV patients on antiretroviral therapy in a resource-limited setting.
    Gambo A; Moodley I; Babashani M; Babalola TK; Gqaleni N
    PLoS One; 2021; 16(12):e0261935. PubMed ID: 34972169
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Treatment of helminth co-infection in HIV-1 infected individuals in resource-limited settings.
    Walson JL; John-Stewart G
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006419. PubMed ID: 18254104
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections.
    Shanmugam V; Switzer WM; Nkengasong JN; García-Lerma G; Green TA; Ekpini E; Sassan-Morokro M; Antunes F; Manshino K; Soriano V; Wiktor SZ; Heneine W
    J Acquir Immune Defic Syndr; 2000 Jul; 24(3):257-63. PubMed ID: 10969350
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immunologic effect of zinc supplementation in HIV-infected children receiving highly active antiretroviral therapy: a randomized, double-blind, placebo-controlled trial.
    Lodha R; Shah N; Mohari N; Mukherjee A; Vajpayee M; Singh R; Singla M; Saini S; Bhatnagar S; Kabra SK
    J Acquir Immune Defic Syndr; 2014 Aug; 66(4):386-92. PubMed ID: 24798767
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults.
    Baum MK; Lai S; Sales S; Page JB; Campa A
    Clin Infect Dis; 2010 Jun; 50(12):1653-60. PubMed ID: 20455705
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals.
    Schifitto G; Deng L; Yeh TM; Evans SR; Ernst T; Zhong J; Clifford D
    J Neurovirol; 2011 Feb; 17(1):17-25. PubMed ID: 21181521
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Chinese herbal medicine for patients living with HIV in Guangxi province, China: an analysis of two registries.
    Sun J; Jiang F; Wen B; Liu ZW; Han M; Robinson N; McGrath N; Fei YT; Zhang Y; Li J; Li WY; Deng X; Liu JP
    Sci Rep; 2019 Nov; 9(1):17444. PubMed ID: 31767895
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial.
    Wilson D; Goggin K; Williams K; Gerkovich MM; Gqaleni N; Syce J; Bartman P; Johnson Q; Folk WR
    PLoS One; 2015; 10(7):e0128522. PubMed ID: 26186450
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study.
    Abrams DI; Shade SB; Couey P; McCune JM; Lo J; Bacchetti P; Chang B; Epling L; Liegler T; Grant RM
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):77-85. PubMed ID: 17263636
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Effect of Immune No. 2 on the immune reconstitution in patients with HIV/AIDS after highly active antiretroviral treatment: a randomized double blind placebo controlled clinical trial.
    Wang J; Li Y; Tang YL; Lin HS; Wu XF; Liu J
    Chin J Integr Med; 2013 May; 19(5):340-6. PubMed ID: 23494328
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial.
    Yang OO; Kelesidis T; Cordova R; Khanlou H
    AIDS Res Hum Retroviruses; 2014 Oct; 30(10):988-95. PubMed ID: 25127924
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The Novel Effects of a Hydrolyzed Polysaccharide Dietary Supplement on Immune, Hepatic, and Renal Function in Adults with HIV in a Randomized, Double-Blind, Placebo-Control Trial.
    Lewis JE; Atlas Bsn SE; Abbas MH; Rasul A; Farooqi A; Lantigua LA; Michaud F; Goldberg S; Lages LC; Higuera OL; Fiallo A; Tiozzo E; Woolger JM; Ciraula S; Mendez A; Rodriguez A; Konefal J
    J Diet Suppl; 2020; 17(4):429-441. PubMed ID: 31146613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.